Bone Metastases Therapeutics - Pipeline Assessment and Market Forecasts to 2017

March 29, 2011 - PRLog -- GlobalData estimates that the global bone metastases therapeutics market was valued at $1,425m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 12% over the next seven years to reach $6,390m by 2017. Although the drug pipeline for the treatment of bone metastases is strong, the launch of Amgen’s Xgeva in early 2010, which is another breakthrough for bone metastases patients, is the primary driver for increased market growth. The market remains well-served with the current marketed products, most of which are significantly efficacious in their respective target areas. Essentially, the global bone metastases market is heading towards a phase of continuous growth, leveraging the current opportunities.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Bone-Metstasis-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

GlobalData analysis shows that the bone metastases therapeutics pipeline is strong, with 10 molecules in various phases of clinical development, including eight first-in-class molecules. Amongst these eight first-in-class molecules, one molecule is in late stage and the remainder is in the early stages of clinical development. The late stage pipeline molecule, alpharadin, is a radiopharmaceutical which is expected to launch by 2014. Orazol, in Phase III clinical trials, is a once weekly oral formulation of zoledronic acid and is expected to hit the market by 2014. Both these products will be responsible for the growth of the bone metastases therapeutics market post- 2014. Although the market is adequately served by the current treatment options, the bone metastases therapeutics pipeline will uncover opportunities for the new entrants.

The bone metastases therapeutics market has moderate unmet need, as the present market is well served with the current treatment options; however, there is a scope for new products in the market. The current marketed products have prolonged duration of therapy, require supervision for administration of the infusion of bisphosphonates, and inadequately target the primary tumor, which is insufficient to meet the demand of the patients. Thus, there is a need for a novel product which can fill the voids created by the currently marketed products. The pipeline products are expected to provide better benefits, with innovative mechanisms of action in comparison to the existing players.

GlobalData, the industry analysis specialist, has released its new report, “Bone Metastases Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global bone metastases therapeutics market. The report identifies the key trends shaping and driving the global bone metastases therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global bone metastases therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Bone...

Visit our report store: http://www.globaldata.com

For more details contact:
pressreleases@globaldata.com            
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.